REKAH PHARMACEUTICAL INDUSTRY LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,311 ILa | -4.10% |
|
-1.87% | -11.30% |
| Sales 2022 | 292M 76.85M 29.24B 6.41B | Sales 2023 | 322M 84.55M 32.17B 7.05B | Capitalization | 169M 44.34M 16.87B 3.7B |
|---|---|---|---|---|---|
| Net income 2022 | -2M -526K -200M -43.82M | Net income 2023 | -6M -1.58M -600M -131M | EV / Sales 2022 | 1.1 x |
| Net Debt 2022 | 145M 38.22M 14.54B 3.19B | Net Debt 2023 | 166M 43.75M 16.64B 3.65B | EV / Sales 2023 | 1.04 x |
| P/E ratio 2022 |
-85.5
x | P/E ratio 2023 |
-24.2
x | Employees | 427 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 17.36% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.10% | ||
| 1 week | -1.87% | ||
| Current month | -4.79% | ||
| 1 month | -4.72% | ||
| 3 months | -7.02% | ||
| 6 months | -20.69% | ||
| Current year | -11.30% |
1 week
1 300.00
1 390.00
1 month
1 271.001 455.00
Current year
1 271.001 507.00
1 year
1 271.001 887.00
3 years
1 271.002 700.00
5 years
1 271.002 908.00
10 years
856.104 076.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 80 | 24/93/24 | |
Yuval Bernshtein
DFI | Director of Finance/CFO | 44 | 01/18/01 |
| Director/Board Member | 78 | 24/93/24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 15/15/15 |
Amiram Boehm
BRD | Director/Board Member | 52 | 15/15/15 |
Avraham Bigger
CHM | Chairman | 77 | 15/15/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 1,311 | -4.10% | 926 |
| 24/24/24 | 1,367 | +2.32% | 101 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 04:54 pm IST
More quotes
Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -11.30% | 39.24M | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| +0.24% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B |
- Stock Market
- Equities
- REKA Stock
